北京銳瑟科技有限公司于1999年成立。成立伊始從事高科技產品的研發與應用。2006年初，公司開始大力向高科技醫療和生物技術領域進軍，同時招募了眾多相關行業精英，整合相關領域資源，完善研發中心、生產基地和營銷渠道，并與國外多家生物技術公司建立了長期合作關系。2009年，公司與RISE TECHNOLOGY Co.,LTD. (USA)達成戰略伙伴關系，取得了生物抗菌多肽技術的專利使用權和專利基礎上的開發權，從而奠定了我公司在生物醫療領域的發展基礎。并成功實現了由技術到產品的轉化，使抗菌多肽產品得以順利邁向了市場。

我公司現已擁有實力雄厚的生物醫學領域專家、博士所組成的研發團隊，對多個具有世界影響的高科技生物課題展開深入研究，并已取得顯著成果。于2013年5月我公司獲得了中華人民共和國國家知識產權局所授予的《用于黏膜組織的抗微生物肽制劑》發明專利；替代人類用抗生素的抗菌肽研究已經進展到了動物實驗階段。

2013年12月，我公司投資控股成立北京銳瑟生物醫藥科技發展有限公司，并成功進駐中關村國家生物醫藥園，同期生物領域尖端技術的生物蛋白肽抗腫瘤轉移藥物開始CFDA的臨床申請工作；殺滅腫瘤細胞的蛋白肽藥物進入動物試驗階段。

2014年11月，我公司投資控股成立北京銳瑟生物醫學研究所，主要開展處于行業領先地位的基因芯片的開發與測序服務。

作為國際ISO9001質量管理體系認證企業，我公司以促進生命健康為使命，注重企業科學化、人性化管理，生產符合人們需求的優質產品。并努力成為中國最優秀的生物醫療技術企業。

Rise Technology Co. Ltd. is a globallybiopharmaceutical company, founded in early twenty-first century，incorporatedin the United States, has its state of the arts research facilities in America,Canada, China and Taiwan. Rise has become a technology leader in the fields ofantimicrobial peptides, biological anticancer drugs, and biomedical materials.Among the innovative biomedical companies, we take the lead in building acomplete pharmaceutical value chain, covering research, development,production, marketing and other aspects. And we are committed to create morevalue by innovation, progress and high profitability.

We are a patient-centered company committedto helping patients prolong their lives and fundamentally improve their qualityof life. Rise has developed over ten antimicrobial peptides drugs, covering thesix areas of oral therapy, gynecology, ophthalmology, surgery, ENT, anddermatology, giving a comprehensive solution to the resistant problem faced bytopical antibiotic and also solving the problem of drug unavailability in themucosal tissue. We have also made a breakthrough in the antitumor field bydeveloping broad spectrum biological anticancer drugs and have achieved goodclinical results.

Taking a patient-oriented attitude, weaccelerate the speed in researching and developing biopharmaceuticals andmedical biomaterials and making plans to prevent and cope with the mostdifficult diseases. As an inventor company, Rise will continue to lead the trendin the research and development of antimicrobial peptides and biologicalanticancer drugs. Innovation is the basis of competitiveness and the origin ofdevelopment, but also the key to the company's future success. Rise is steppingforward its goal to become the most valuable biomedical business in the world.